Clinical Guidelines from NICE related to endocrine disease can be found here
Vial - 10ml
Cartridges for Autopen Classic or HumaPen
Vial - 10ml
Cartridges for ClickSTAR & Autopen, Solostar prefilled pen
Vial - 10ml
Cartridges for ClickSTAR and Autopen 24, Solostar prefilled device
Vial - 10ml
Cartridges for Insulatard penfill, Insulatard Innolet prefilled device
Vial - 10ml
Cartridges for Autopen Classic or HumaPen, Humulin I KwikPen prefilled device
5 × 3-mL Penfill® cartridges (for Novo Nordisk® devices) 100 units/mL,
5 × 3-mL FlexTouch® prefilled disposable injection devices (range 1– 80 units, allowing 1-unit dosage adjustment)
Also available as 200units / ml. NOT on formulary at this strength. For initiation by Consultant only for Type 1 diabetic patients who remain at significant risk of hypoglycaemia despite intensive insulin treatment
50 micrograms/mL, 10 micrograms/dose prefilled pen, 100 micrograms/mL, 20 micrograms/dose prefilled pen
1.5 mg solution for injection in a pre-filled pen
GLP-1 first line option is Lixisenatide, second line Dulaglutide. Liraglutide and Exenatide are approved by NICE and may be considered on an individual patient basis but are considered less cost effective than the other two agents.
Tablets - 10mg, 25mg
Approved by NICE as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated, and when diet and exercise alone do not provide adequate glycaemic control, only if:
Tablets - 100mg
Approved by NICE as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated, and when diet and exercise alone do not provide adequate glycaemic control, only if:
Tablets - 5mg, 10mg
Approved by NICE as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated, and when diet and exercise alone do not provide adequate glycaemic control, only if:
Tablets - 5mg
BNF states: Neutropenia and agranulocytosis: Doctors are reminded of the importance of recognising bone marrow suppression induced by carbimazole and the need to stop treatment promptly.
Patient should be asked to report symptoms and signs suggestive of infection, especially sore throat.
A white blood cell count should be performed if there is any clinical evidence of infection.
Carbimazole should be stopped promptly if there is clinical or laboratory evidence of neutropenia.
Tablets - 1mg, 5mg, 25mg
Tablets soluble - 5mg
Oral solution - 1mg/1ml (Prednisolone Dompé)
There are no clinical benefits from prescribing prednisolone as enteric coated tablets. The risk of gastro-intestinal side-effects are no higher with plain tablets, especially if the patient takes the tablets with food.
Lowest cost formulation to be used when clinically appropriate
Tablets - 300micrograms oestrogen & 1.5mg medroxyporgesterone
Patches - 50microgram/24hours estradiol & 170microgram/24hours norethisterone
Patches - 50microgram/24hours estradiol & 7microgram/24hours levonorgestrel
Patches - 25micrograms/24hours, 50micrograms/24hours75micrograms/24hours, 100microgram/24hours estradiol
Tablets - 50mg, 100mg
Approved for use on the advice of a urologist
50mg in 5gram (1%) gel - For use on advice from endocrinologists
50mg in 5ml (1%) sachets - For use on advice of endocrinologist
10mg in 0.5ml (2%)/metered dose gel pump - For use on advice from endocrinologist
Tablets - 100micrograms, 200micrograms
Nasal Spray - 10micrograms/metered spray
Injection - 60mg/ml
Consultant initiation only. Recommended by NICE as an option in treatment of secondary or primary prevention of osteoporotic fragility fractures in post-menopuasal women only when unable to tolerate, comply with administration instructions or contraindicated to at least two bisphosphonates
Powder sachet - 2g
Contraindicated in current or previous VTE, IHD, PAD, cerebrovascular disease, uncontrolled hypertension, temporary or prolonged immobilisation. Severe allergic reactions including DRESS have been reported. Patients must discontinue and treatment should not be restarted